Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Seattle Genetics, Inc.
Type
Public
Traded as NASDAQ: SGEN
Industry Biotechnology, Pharmaceutical
Founded Incorporated 15 July 1997
Headquarters Bothell, Washington, United States
Key people
Clay B. Siegall Ph.D
(Chairman, President & CEO)
Todd E. Simpson
(CFO
Eric L. Dobmeier
(Chief Operating Officer)
Jean Liu
(Executive Vice President Legal Affairs, General Counsel, Corporate Secretary)
Jonathan Drachman M.D.
(Chief Medical Officer) and Executive Vice President of R&D)
Vaughn Himes
(Executive Vice President) Technical Operations and Process Sciences
Charles Romp
(Senior Vice President) Sales
Felix Baker
Lead Independent Director
Pinkston Peggy
Senior Director Corporate Communications
Products Brentuximab vedotin and other Antibody-drug conjugates
Number of employees
> 650
Website www.seattlegenetics.com

Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington (a suburb of Seattle), is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug Conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.

The companys' flagship product Adcetris (Brentuximab vedotin) is commercially available for two indications in 50 countries, including the U.S., Canada, Japan and members of the European Union. The approval of Brentuximab vedotin makes it the first in a new class of ADCs.

To expand on the clinical opportunities of brentuximab vedotin, Seattle Genetics is conducting a broad clinical development program to evaluate its therapeutic potential in earlier lines of its approved indications as well as in a range of other lymphoma and non-lymphoma settings. The company is jointly developing brentuximab vedotin in collaboration with Takeda Pharmaceutical Company. Under the terms of the collaboration, Seattle Genetics has full commercialization rights to brentuximab vedotin in the United States and Canada. Takeda has exclusive rights to commercialize the product candidate in all other countries.

In addition to brentuximab vedotin, Seattle Genetics' product pipeline includes SGN-CD19A, an Antibody-drug conjugate (ADC) targeting CD19, SGN-CD33A, an ADC targeting CD33, SGN-LIV1A, an ADC targeting LIV-1, SGN-CD70A, an ADC targeting CD70, as well as ASG-22ME and ASG-15ME, ADCs that they are co-developing with Agensys (an affiliate of Astellas), an early-stage privately held biotechnology company based in Los Angeles, focusing on the development of fully human monoclonal antibodies to treat solid tumor cancers in a variety of cancer targets.

Seattle Genetics has collaboration agreements with Takeda Oncology Company (formerly Millennium) to develop and commercialize brentuximab vedotin. The company also has collaboration agreements for their ADC technology with a number of biotechnology and pharmaceutical companies, including, AbbVie, Bayer Celldex Therapeutics, Inc., Daiichi Sankyo, Genentech, Inc., GlaxoSmithKline, Pfizer, Inc. and PSMA Development Company LLC as well as ADC co-development agreements with Agensys, Inc., an affiliate of Astellas Pharma and Oxford BioTherapeutics Ltd.

Seattle Genetics' proprietary Monomethyl auristatin E or MMAE-based antibody-drug conjugate technology, employed in brentuximab vedotin, empowers monoclonal antibodies to treat cancer. Brentuximab vedotin, for example, links the chimeric anti-CD30 monoclonal antibody (cAC10) via a protease-cleavable linker to MMAE. This ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells. This approach is intended to spare non-targeted (healthy) cells and thus reduce many of the toxic effects of traditional chemotherapy while potentially enhancing antitumor activity. (See also vedotins)

Seattle Genetics is also evaluating another ADC technology using a highly potent cytotoxic agent called a pyrrolobenzodiazepine (PBD) dimer that kills cells by a different mechanism than auristatins (monomethyl auristatin E or monomethyl auristatin F). Pyrrolobenzodiazepine (PBD) dimer is currently employed in SGN-CD33A and SGN-CD70A. It is stably linked to an antibody with Seattle Genetics' site-specific engineered cysteines, resulting in uniform drug-loading of two PBD dimers per antibody.

Seattle Genetics was founded in 1997 and is headquartered in Bothell, Washington, a suburb of Seattle. The company completed an initial public offering in March 2001, and is traded on the Nasdaq Stock Market under the symbol SGEN. To date, the company has more than 650 employees throughout the United States.

Seattle Genetics was named number twenty-five on the list of Top 25 Biotech Companies of 2016.

Investment goal date:
Dividends reinvested
Seattle Genetics, Inc. SGEN report Q3 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q1 2018
2018-04-28
--
--
Q4 2017
2018-02-07
--
--
Q3 2017
2017-10-26
-0.1900
0.3400
Q2 2017
2017-07-27
-0.3900
-0.3900
Q1 2017
2017-04-27
-0.4200
-0.4200
Q4 2016
2017-02-09
-0.3900
-0.3900
Q3 2016
2016-10-27
-0.2300
-0.2300
Q2 2016
2016-07-26
-0.2300
-0.2300
Q1 2016
2016-04-28
-0.1500
-0.1500
Q4 2015
2016-02-09
-0.1800
-0.1800
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
Artisan Partners Limited Partnership
1273698
BAILLIE GIFFORD & CO
16196553
BAKER BROS. ADVISORS LP
45715556
BlackRock Fund Advisors
3110333
BlackRock Inc.
7267660
BlackRock Institutional Trust Company, N.A.
2649393
Capital International Investors
2028603
FMR LLC
10173597
Matrix Capital Management Company, LP
1783000
OPPENHEIMER FUNDS INC
1400000
PRICE T ROWE ASSOCIATES INC /MD/
3766728
PRIMECAP MANAGEMENT CO/CA/
13182312
STATE STREET CORP
2845120
Vanguard Group, Inc
7362687
WASATCH ADVISORS INC
1934882
Major Shareholders
Name Relationship
Total Shares
Holding stocks
BAKER FELIX
31.4200% (38787087)
SIEGALL CLAY B
0.5600% (687146)
ALDR / SGEN /
GRYSKA DAVID W
0.0200% (23950)
DOBMEIER ERIC
0.1000% (117424)
ATRA / SGEN / STML / VSAR /
LIPPMAN MARC E
0.1000% (117950)
SGEN /
WELCH DANIEL G
0.0300% (41819)
HPTX / ICPT / ITMN / SGEN /
SIMPSON TODD E
0.1400% (178992)
AQXP / SGEN / TGEN /
SIMPSON TODD E
0.1800% (218377)
AQXP / SGEN / TGEN /
AKKARAJU SRINIVAS
0.0100% (13905)
ICPT / SGEN / VSAR / ZSPH /
BAKER BROS. ADVISORS LP
33.1300% (40898792)
BERGER FRANKLIN M
0.1700% (204720)
HIMES VAUGHN B
0.1300% (164906)
SGEN /
Reynolds Thomas C
0.0500% (57601)
MEIP / SGEN /
Orwin John A
0.0100% (10700)
AFFY / ARRY / RLYP / SGEN /
BOERNER CHRISTOPHER S.
0.0500% (56358)
AKAO / SGEN /
DRACHMAN JONATHAN G
0.1200% (151518)
CALA / SGEN /
% ()